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SREBP-1 integrates the actions of thyroid hormone,
insulin, cAMP, and medium-chain fatty acids
on ACC transcription in hepatocytes
Yanqiao Zhang, Liya Yin, and F. Bradley Hillgartner1
Department of Biochemistry and Molecular Pharmacology, School of Medicine, P.O. Box 9142, West Virginia
University, Morgantown, WV

Abstract In chick embryo hepatocytes, activation of acetylCoA carboxylase- (ACC) transcription by 3,5,3-triiodothyronine (T3) is mediated by a cis-acting regulatory unit
(101 to 71 bp) that binds the nuclear T3 receptor (TR)
and sterol regulatory element-binding protein-1 (SREBP-1).
SREBP-1 directly interacts with TR on the ACC gene to enhance T3-induced transcription. Here, we show that treating
hepatocytes with T3 or insulin stimulates a 4-fold increase
in the concentration of the mature, active form of SREBP-1.
When T3 and insulin are added together, a 7-fold increase
in the mature SREBP-1 concentration is observed. Time
course studies indicate that the T3-induced increase in mature SREBP-1 abundance is closely associated with changes
in ACC transcription and that the mechanism mediating
the effect of T3 on mature SREBP-1 is distinct from that
mediating the effect of insulin. Transfection analyses indicate that inhibition of ACC transcription by cAMP or hexanoate is mediated by ACC sequences between 101 and
71 bp. Treatment with cAMP or hexanoate suppresses the
increase in mature SREBP-1 abundance caused by T3 and
insulin. These results establish a new interaction between
the SREBP-1 and TR signaling pathways and provide evidence
that SREBP-1 plays an active role in mediating the effects of
T3, insulin, cAMP, and hexanoate on ACC transcription.—
Zhang, Y., L. Yin, and F. B. Hillgartner. SREBP-1 integrates
the actions of thyroid hormone, insulin, cAMP, and mediumchain fatty acids on ACC transcription in hepatocytes. J.
Lipid Res. 2003. 44: 356–368.
Supplementary key words lipogenesis • hexanoate • nuclear T3 receptor • liver X receptor • chicken • fatty acid synthesis • liver • sterol
regulatory element binding protein • adenosine 3,5-cyclic monophosphate • acetyl-CoA carboxylase-

In livers of avians and mammals, consumption of a highcarbohydrate, low-fat diet coordinately stimulates the transcription of genes involved in the conversion of carbohydrate
to triacylglycerols (1). These genes include glucokinase,
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l-pyruvate kinase, ATP-citrate lyase, acetyl-CoA carboxylase-
(ACC), fatty acid synthase, malic enzyme, and glycerol-3phosphate acyltransferase. To date, three signaling pathways
have been identified that mediate the effects of dietary carbohydrate on lipogenic gene transcription. One pathway is activated by increased glucose metabolism, and its end target is
carbohydrate response factor or carbohydrate response element binding protein (ChREBP) (2, 3). Increased glucose
metabolism enhances the ability of ChREBP to bind the
l-pyruvate kinase gene and activate l-pyruvate kinase transcription (2). A second pathway that signals changes in carbohydrate consumption to lipogenic genes is activated by
3,5,3-triiodothyronine (T3), the active form of thyroid hormone (1). T3 activates transcription through its interactions
with nuclear T3 receptors (TRs) bound to T3 response elements (T3REs) of target genes (4). Functional T3REs have
been identified in the genes for ACC (5), fatty acid synthase
(6), and malic enzyme (7). A third pathway that signals alterations in dietary carbohydrate status to lipogenic genes is activated by insulin, and its end target is sterol regulatory
element binding protein (SREBP)-1 (8, 9). SREBP-1 is synthesized as a 125 kDa precursor protein that is anchored to the
endoplasmic reticulum. To become transcriptionally active,
precursor SREBP-1 is translocated to Golgi, where it is cleaved
by two proteases, resulting in the release of the N-terminal
segment of SREBP-1, referred to as mature SREBP-1. Mature
SREBP-1 is transported into the nucleus, where it binds the
promoter/regulatory regions of several lipogenic genes, including ACC (10) and fatty acid synthase (11, 12). In rat
hepatocytes, insulin increases the concentration of mature
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SREBP-1, resulting in an activation lipogenic gene transcription (13–15).
The ChREBP, TR, and SREBP-1 signaling pathways also
mediate the effects of nutrients and hormones that inhibit
lipogenic gene transcription. For example, long-chain
fatty acids suppress the activation of ChREBP, TR, and
SREBP-1 by glucose, T3, and insulin, respectively (16–20).
Glucagon, a hormone that signals the starved state in animals, also inhibits the activation of ChREBP by glucose
(2). Whether glucagon inhibits lipogenic gene transcription by suppressing positive signaling through the TR or
SREBP-1 pathways is presently not known.
ACC catalyzes the ATP-dependent carboxylation of
acetyl-CoA to malonyl-CoA, which is the donor of all but
two of the carbon atoms for the synthesis of long-chain
fatty acids. This reaction is the pace-setting step of the
fatty acid synthesis pathway (1). There are two ACC isoforms that are encoded by distinct genes. ACC is the
principal isoform expressed in heart and skeletal muscle,
where it is thought to function primarily in the regulation
of -oxidation of fatty acids (21). ACC is the major isoform expressed in tissues such as liver and adipose tissue
that exhibit high rates of fatty acid synthesis. Transcription of the ACC gene is subject to nutritional regulation.
For example, in livers of starved chickens, the rate of
ACC transcription is low; consumption of a high-carbohydrate, low-fat diet stimulates an 11-fold increase in
ACC transcription (22). The induction of ACC transcription caused by dietary carbohydrate is preceded or
paralleled by increases in the molar ratio of insulin/glucagon and the level of T3 in the blood (23). In primary cultures of chick embryo hepatocytes (CEHs), addition of T3
to the culture medium stimulates a 7-fold increase in
ACC transcription (24). Insulin has no effect by itself but
amplifies the increase in ACC transcription caused by
T3. Glucagon acting through cAMP suppresses the induction of ACC transcription caused by T3 and insulin.
Fatty acids containing six to eight carbons also inhibit
ACC transcription in the presence of T3 and insulin and
do so within 2 h of addition of the fatty acid (25, 26). Hexanoate and octanoate per se are not likely to be physiological regulators of ACC transcription, because the levels
of these fatty acids in the blood are not high enough to inhibit transcription. However, the potent, rapid, and selective effects of hexanoate and octanoate on ACC transcription suggest that the intracellular intermediates and
signaling pathways mediating the effects of these fatty acids on transcription are physiologically relevant (25). For
example, during starvation, a condition in which ACC
transcription is inhibited, increased rates of fatty acid oxidation may cause a change in the level of a metabolic intermediate that, in turn, inhibits ACC transcription. In
hepatocytes in culture, addition of hexanoate and octanoate to the culture medium may mimic the effects of
starvation on the level of this intermediate. The identity of
the active intermediate(s) mediating the effects of hexanoate and octanoate on ACC transcription is of interest
because it may aid in the development of new therapies to
prevent and treat obesity and cardiovascular disease.

The ACC gene is transcribed from two promoters,
generating mRNAs with heterogeneity in their 5-untranslated regions (27). Alterations in the activity of the more
downstream promoter (promoter 2) account for the majority of the changes in ACC mRNA abundance caused
by starvation and refeeding a high-carbohydrate diet in intact chickens and by T3, insulin, cAMP, and hexanoate in
CEH (26). The stimulatory effect of T3 on ACC promoter 2 activity is mediated by a T3RE (101 to 86 bp)
that enhances ACC transcription in both the absence
and the presence of T3, with a greater stimulation observed in the presence of T3 (5). The enhancer activity in
the absence of T3 is mediated by the binding of protein
complexes containing liver X receptor (LXR)·retinoid X
receptor (RXR) heterodimers. The increase in enhancer
activity caused by T3 treatment is mediated by the binding
of a different set of protein complexes. One of these complexes contains TR·RXR heterodimers, and another contains LXR·RXR heterodimers. Immediately downstream
of the ACC T3RE is a sterol regulatory element (SRE)-1
(80 to 71 bp) that augments the ability of the ACC
T3RE to stimulate ACC transcription in the presence of
T3 (10). Results from transfection, protein binding, and
DNA binding assays suggest that the stimulatory effect of
the SRE-1 on ACC transcription is mediated by a direct
and T3-inducible interaction between SREBP-1 and TR
and that this interaction facilitates the formation of a
SREBP-1·SREBP-1/TR·RXR tetrameric complex on the
ACC gene. Complex formation between TR·RXR and
SREBP-1·SREBP-1 stabilizes the binding of SREBP-1 to the
SRE-1. Thus, optimal induction of ACC transcription by
T3 is dependent on an interaction between TR and
SREBP-1 on the ACC gene. Both of these signaling pathways represent potential targets mediating the actions of
insulin, cAMP, and medium-chain fatty acids on T3-induced
ACC transcription. The mechanisms by which insulin,
cAMP, and medium-chain fatty acids control ACC transcription remain to be determined.
In the present study, we have identified a new interaction between the SREBP-1 and TR signaling pathways. T3
increases the concentration of the mature, active form of
SREBP-1 in CEH. In addition, we provide evidence that insulin, cAMP, and medium-chain fatty acids regulate ACC
transcription by modulating the abundance of mature
SREBP-1.

EXPERIMENTAL PROCEDURES
Plasmids
Reporter plasmids are named by designating the 5- and 3- ends
of the ACC DNA fragment relative to the transcription start site of
promoter 2. A series of 5-deletions and 3-deletions of ACC promoter 2 gene in the context of p[ACC4900/274] chloramphenicol acetyltransferase (CAT) have been previously described
(5). ACC promoter constructs containing mutations of the SRE-1
between 79 and 72 bp have been described previously (10).
pBLCAT2 (pTKCAT) was obtained from B. Luckow and G. Schutz
(German Cancer Research Center) (28). p[ACC108/82]TK-
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CAT, p[ACC108/66]TKCAT, p[ACC84/66]TKCAT, and
pTKCAT constructs containing mutations in the 108 to 66 bp
ACC fragment are described in (10).
A full-length cDNA for chicken SREBP-1 was obtained by
screening a chicken liver cDNA library (Stratagene) using a human SREBP-1 cDNA probe (nucleotides 721 to 1,103 relative to
the start site of translation) and by 5-rapid amplification of
cDNA ends (RACE) (Y. Zhang and F. B. Hillgartner, unpublished
observations). The N-terminal amino acid sequence of this
chicken SREBP-1 (GenBank accession number: AY029224) more
closely resembles the 1a isoform than the 1c isoform described in
mammalian species (29). Data from 5-RACE and RNase protection analyses indicate that other forms of SREBP-1 containing
variations in the N-terminus are not expressed in chicken cells.
An expression plasmid encoding the mature form of chicken
SREBP-1 was developed by subcloning an SREBP-1 cDNA fragment encoding amino acids 1 to 464 into pSV-SPORT1 (Invitrogen) to form pSV-SPORT1-SREBP-1 (1-464).

Cell culture and transient transfection
Primary cultures of CEH were prepared as previously described (30) and maintained in serum-free Waymouth’s medium
MD705/1 containing 1 M corticosterone, 50 nM insulin (gift
from Eli Lilly Corp.), and 25 mM glucose. CEHs were incubated
at 40C in a humidified atmosphere of 5% CO2 and 95% air.
CEHs were transfected using a modification of the method of
Baillie et al. (31). Briefly, CEHs were isolated as described above
and incubated on 60 mm petri dishes (Fisher Scientific). At 6 h
of incubation, the medium was replaced with one containing 20 g
of lipofectin (Invitrogen), 2.5 g of p[ACC4900/274]CAT or
an equimolar amount of another reporter plasmid and pBluescript KS() to bring the total amount of transfected DNA to 3.0
g per plate. At 18 h of incubation, the transfection medium was
replaced with fresh medium containing corticosterone, insulin,
25 mM glucose, and T3 (1.5 M). On some cells, the medium
was supplemented with dibutyryl cAMP (50 M) or hexanoate
(2.5 mM). At 66 h of incubation, CEHs were harvested and cell
extracts were prepared (31). CAT activity (32) and protein (33)
were assayed by the indicated methods. All DNAs used in transfection experiments were purified using the Qiagen endotoxin-free kit.

Preparation of membrane and nuclear extracts
All procedures were carried out at 4C. To prevent proteolysis,
a mixture of protease inhibitors (Complete, Roche Molecular
Biochemicals) was included in all the buffers. Nuclear extracts
were prepared from CEHs by a modification of the method described by Dignam et al. (34). Briefly, CEHs from four 100 mm
plates were pooled and centrifuged at 1,000 g for 5 min at 4C.
The resulting cell pellet was homogenized in Buffer 1 [10 mM
Hepes (pH 7.9), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM dithiothreitol] using 20 strokes in a Dounce homogenizer. The homogenate was centrifuged at 1,100 g for 10
min, and the resulting nuclear pellet was washed once in buffer
1. The nuclear pellet was resuspended in Buffer 2 [20 mM Hepes
(pH 7.9), 420 mM NaCl, 25% (v/v) glycerol, 1.5 mM MgCl2, 1
mM EDTA, 1 mM EGTA, 1 mM dithiothreitol]. This suspension
was rotated for 30 min and then centrifuged 15,000 g for 30 min.
The resulting supernatant is designated as the nuclear extract
fraction. The membrane extract fraction was prepared by centrifuging the supernatant of the original 1,100 g spin for 1 h at
100,000 g. The resulting membrane pellet was dissolved in Buffer
3 [10 mM Tris (pH 6.8), 100 mM NaCl, 1% (w/v) SDS, 1 mM
EDTA, 1 mM EGTA, 1 mM dithiothreitol]. The protein content
of the nuclear and membrane extracts was determined as described (33).
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Gel mobility shift analysis
Double-stranded oligonucleotides were prepared by combining equal amounts of the complementary single-stranded DNA
in a solution containing 10 mM Tris (pH 8.0) and 1 mM EDTA
followed by heating to 90C for 2 min, and then cooling to room
temperature. The annealed oligonucleotides were labeled by filling in overhanging 5-ends using the Klenow fragment of Escherichia coli DNA polymerase in the presence of [-32P]dCTP and/or
[-32P]dGTP. Binding reactions were carried out in 20 l of 20
mM Tris (pH 7.9), 100 mM KCl, 5 mM MgCl2, 1 mM EDTA, 1
mM dithiothreitol, 5% glycerol (v/v), 0.3 mg/ml BSA, and 2 g
of poly[d(I·C)]. A typical reaction contained 20,000 cpm of
labeled DNA and 20 g of nuclear extract. The reactions were
performed at 20C for 20 min (ACC SRE-1 probe) (Figs. 1A, B,
7B) or on ice for 60 min (ACC T3RE probe, Fig. 6). DNA and
DNA-protein complexes were resolved on 6% nondenaturing
polyacrylamide gels at 4C in 0.5 TBE (45 mM Tris (pH 8.3),
45 mM boric acid, 1 mM EDTA). Following electrophoresis,
the gels were dried and subjected to storage phosphor autoradiography. For competition experiments, unlabeled competitor
DNA was mixed with radiolabeled oligomer prior to addition of
nuclear extract. For antibody supershift experiments, nuclear extracts were incubated with antibodies for 30 min prior to addition of the oligonucleotide probe. Mouse monoclonal antibodies
against SREBP-1 (IgG-2A4) and SREBP-2 (IgG-1D2) were obtained from American Type Tissue Collection (Manassas, VA).
The sequence of ACC SRE-1 probe and ACC T3RE probe was
5-TCGCATCACACCACCGCGG-3 and 5-AGGTGGTTGACCCGA
GGTTAACCCCTCG-3, respectively.

Western blot analysis
Proteins in nuclear extract and membrane fractions were subjected to electrophoresis in 8% SDS-polyacrylamide gels and
then transferred to PDVF membranes (Amersham Pharmacia)
using an electroblotting apparatus (Owl Scientific). Immunoblot
analyses were performed as described in the Western blotting
protocol from Santa Cruz Biotechnology. Briefly, the blots were
blocked in Blotto [5% nonfat dry milk, 10 mM Tris-HCl (pH
8.0), 150 mM NaCl] at 4C overnight, and then incubated with
monoclonal antibody against SREBP-1 (IgG-2A4) diluted to 1
g/ml in Blotto containing 0.01% (v/v) Tween-20. After incubation with primary antibody for 1 h at room temperature, the
blots were washed in TBS [10 mM Tris-HCl (pH 8.0), 150 mM
NaCl] containing 0.01% Tween-20. Next, the blots were incubated with a donkey anti-mouse IgG conjugated to horseradish
peroxidase (Jackson ImmunoResearch) diluted 1:10,000 in
Blotto, 0.01% Tween-20 for 1 h at room temperature. After washing with TBS, 0.01% Tween-20, antibody/protein complexes on
blots were detected using enhanced chemiluminescence (Amersham Pharmacia). Chemiluminescence on the blots was visualized
using a FluorChem 8000 imager (Alpha Innotech Corporation),
and signals for the precursor and mature forms of SREBP-1 were
quantified using FluorChem V200 software.

RNase protection assay
A chicken SREBP-1 cDNA fragment (300 bp) containing sequences between nucleotides 829 and 1,128 relative to the start
site of translation was subcloned into the HindIII and BamHI sites
of pBluescript KS (Stratagene). The subclone was linearized with
BamHI, and antisense RNA was transcribed with -[32P]CTP (specific activity 3,000 Ci/mmol) using bacteriophage T3 RNA polymerase (Promega). An 18 S rRNA probe, which was used as a
control for RNA loading, was made from pRTI 18 S template
(Ambion, Austin, TX). Labeled RNAs were purified by polyacrylamide gel electrophoresis. RNA was extracted from CEH by the
guanidinium thiocyanate-phenol-chloroform method (35).

RNase protection assays were performed using the RPA II kit (Ambion). Total RNA (20 g) was hybridized to 4 104 cpm of 32Plabeled RNA at 45C for 16 h. The sample was then digested with a
mixture of RNase A and RNase T. Protected fragments were separated on 8 M urea/5% polyacrylamide gels. Gels were dried and
subjected to storage phosphor autoradiography. Images were
quantified using ImageQuaNT software by Molecular Dynamics.

RESULTS
T3 and insulin increase the concentration of mature
SREBP-1 in CEH
In a previous report, we showed that the mature form of
SREBP-1 interacted with TR on the ACC gene to enhance the stimulatory effect of T3 on ACC transcription
in CEH (10). This observation plus other work demonstrating a role of T3 in signaling changes in dietary carbohydrate status to lipogenic genes (1) have led us to hypothesize that T3 modulates SREBP levels in CEH. As
insulin enhances the ability of T3 to activate ACC transcription in CEH (24), we have further hypothesized that
insulin controls SREBP levels. As a first step in investigating these questions, gel mobility shift experiments were
performed to assess the binding of SREBP to the ACC
SRE-1 in CEH. Incubation of a 32P-labeled oligonucleotide probe containing the ACC SRE-1 (84 to 66 bp)
with nuclear extracts from CEH resulted in the formation
of three protein-DNA complexes (Fig. 1A, left panel). The
binding activity of the upper two complexes was specific,
insofar as it was competed by a 100-fold molar excess of
unlabeled ACC SRE-1 probe but not by a 100-fold molar
excess of an oligonucleotide containing an unrelated sequence. These complexes were designated a and b in the
order of increasing mobility. Preincubation of nuclear extract with an antibody against SREBP-1 disrupted the formation of complex a but had no effect on the formation
of complex b. Preincubation of nuclear extract with an antibody against SREBP-2 had no effect on the formation of
complex a and complex b. Incubation of the ACC SRE-1
probe with in vitro synthesized mature SREBP-1 (amino
acids 1 to 464) resulted in the formation of a SREBP-1 homodimeric complex whose migration was identical to that
of complex a (Fig. 1A, right panel). Collectively, these
data suggest that complex a is comprised of SREBP-1 homodimers and that SREBP-1 is the predominant isoform
of SREBP that binds ACC promoter 2 in CEH. The identity of the proteins in complex b is presently unclear. Previous work has shown that the SRE-1 binds multiple protein
complexes in crude nuclear extracts and that the transcriptional activity of the SRE-1 is correlated only with the
binding of nuclear complexes containing SREBP (36, 37).
Thus, complex a containing SREBP-1 homodimers likely
accounts for the activity of the ACC SRE-1 in CEH.
In CEH incubated in the absence of hormones, the
binding of complex a to the ACC SRE-1 was barely detectable (Fig. 1B). Addition of T3 or insulin to the culture
medium for 24 h stimulated an increase in the binding of

complex a. A greater stimulation of complex a binding activity was observed when T3 and insulin were added together. Thus, T3 and insulin enhance the binding of
SREBP-1 to the ACC SRE-1 in CEH. To determine
whether the increase in SREBP-1 binding activity caused
by T3 and insulin was associated with an elevation in the
amount of mature SREBP-1, Western analyses were performed using nuclear extracts from CEH. In CEH incubated in medium containing high glucose (25 mM), treatment with T3, insulin, or T3 plus insulin for 24 h
increased the concentration of mature SREBP-1 (Fig. 1C,
E). The extent of the increase in mature SREBP-1 concentration caused by T3, insulin, and T3 plus insulin was 4.5-,
4.4-, and 7.0-fold, respectively. Similar effects of T3, insulin, and T3 plus insulin on mature SREBP-1 levels were
observed when CEHs were incubated in medium containing low glucose (5 mM). Treatment of CEH with T3, insulin, or T3 plus insulin in the presence of 5 mM glucose or
25 mM glucose also increased the level of precursor
SREBP-1 in membranes, but the extent of the effect of
these treatments (1.5- to 2.0-fold) was substantially less
than that observed for mature SREBP-1 (Fig. 1C, E). This
observation suggests that alterations in the synthesis of
precursor SREBP-1 account for part of the effects of T3
and insulin on mature SREBP-1 levels. T3 and insulin may
also modulate the proteolytic processing of precursor
SREBP-1 to mature SREBP-1 or the turnover of mature
SREBP-1.
The abundance of SREBP-1 mRNA was also measured
in CEH during different hormonal conditions. In CEH incubated in medium containing 25 mM glucose, addition
of T3, insulin, or T3 plus insulin for 24 h increased the
abundance of SREBP-1 mRNA (Fig. 1D, E). The magnitude of the increase in SREBP-1 mRNA abundance caused
by T3, insulin, and T3 plus insulin was 2.0-, 1.6-, and 2.4fold, respectively. Similar effects of T3, insulin, and T3
plus insulin on SREBP-1 mRNA abundance were observed
in CEH incubated in medium containing 5 mM glucose.
These results provide further evidence that alterations in
the synthesis of precursor SREBP-1 account for part of the
increase in mature SREBP-1 concentration caused by T3
and insulin.
To further analyze the mechanism mediating the effects
of T3 and insulin on SREBP-1 levels in CEH, the time
course of the effects of T3, insulin, and T3 plus insulin on
the abundance of mature SREBP-1 protein, precursor
SREBP-1 protein, and SREBP-1 mRNA was determined in
CEH incubated in medium containing 25 mM glucose.
Treatment of CEH with T3 for 2 h had no effect on the
concentration of mature SREBP-1 (Fig. 2A, C). A small increase in mature SREBP-1 concentration (1.5-fold) was
observed at 6 h of T3 treatment. A substantially larger increase in mature SREBP-1 concentration (4.2-fold) was
observed at 24 h of T3 treatment. Longer incubations with
T3 did not result in a further stimulation of mature
SREBP-1 concentration (data not shown). The increase in
precursor SREBP-1 protein and SREBP-1 mRNA levels
caused by T3 was also maximal at 24 h of treatment. Incubating CEH with T3 for 24 h increased the amount of pre-
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Fig. 1. 3,5,3-Triiodothyronine (T3) and insulin increase the concentration of mature sterol regulatory element binding protein (SREBP)-1 in
chick embryo hepatocytes (CEHs). Hepatocytes were isolated from livers of 18-day-old chick embryos and incubated in serum-free Waymouth’s
medium containing corticosterone and 5 mM glucose. At 18 h of incubation, the medium was changed to one of the same composition or to one
containing corticosterone and 25 mM glucose. T3, insulin, or T3 plus insulin was added at this time. At 42 h of incubation, cellular extracts or total RNA were prepared as described under Experimental Procedures. A: Gel mobility shift assays were per formed using nuclear extracts from
hepatocytes or in vitro synthesized mature SREBP-1 (amino acids 1 to 464) and an oligonucleotide probe containing the acetyl-CoA carboxylase-
(ACC) sterol regulatory element (SRE)-1 (84 to 66 bp). Positions of specific protein-DNA complexes (arrows) and nonspecific complexes
(asterisk) are indicated. Left panel: The ACC SRE-1 probe was incubated with nuclear extract from hepatocytes treated with T3 plus insulin in
the presence of 25 mM glucose. In some incubations, nuclear extract was incubated with antibodies against SREBP-1 or SREBP-2 prior to addition of the probe. Competition analysis was performed by mixing the labeled probe with a 100-fold molar excess of unlabeled probe (self competition) or unrelated sequence (nonspecific competition) prior to the addition of nuclear extract. Right panel: Comparison of the migration of
complex a with that of SREBP-1 dimers bound to the ACC SRE-1 probe. The ACC SRE-1 probe was incubated with in vitro synthesized mature
SREBP-1 or nuclear extract from hepatocytes treated with T3 plus insulin in the presence of 25 mM glucose. B: Gel mobility shift assays were performed using the ACC SRE-1 probe and nuclear extracts from hepatocytes treated with T3, insulin, or T3 plus insulin in the presence of 25 mM
glucose. Positions of specific protein-DNA complexes (arrows) and nonspecific complexes (asterisk) are indicated. C: The abundance of precursor SREBP-1 in membrane fractions and mature SREBP-1 in nuclear extracts was measured by Western analyses. These data are from a representative experiment. D: The abundance of SREBP-1 mRNA and 18S rRNA was measured using an RNase protection assay. These data are from a
representative experiment. E: Signals for precursor SREBP-1 protein and mature SREBP-1 protein from Western analyses and SREBP-1 mRNA
from RNase protection analyses were quantitated. Levels of precursor SREBP-1 protein, mature SREBP-1 protein, and SREBP-1 mRNA in hepatocytes treated with 5 mM glucose and no additional hormones were set at 1. Values are the means SEM of four experiments. a: Mean is significantly (P 0.05) different from that of cells treated with 5 mM glucose and no additional hormones. b: Mean is significantly (P 0.05) different
from that of cells treated with 25 mM glucose and no additional hormones. Experimental details for Western and RNase protection analyses are
described in Experimental Procedures.

cursor SREBP-1 protein and SREBP-1 mRNA by 1.6- and
1.9-fold, respectively (Fig. 2).
In contrast to the delayed effect of T3 on the abundance of
mature SREBP-1, insulin caused a rapid increase in the abundance of mature SREBP-1 in CEH. Treatment with insulin for
2 h stimulated a 3.3-fold increase in the concentration of
mature SREBP-1. Insulin also increased the concentration of
360
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mature SREBP-1 at 6 h (3.4-fold) and 24 h (4.0-fold) of treatment. The difference between T3 and insulin in the time
course of induction of mature SREBP-1 levels suggests that
these hormones act through different mechanisms to enhance the abundance of mature SREBP-1 in CEH. Whereas
insulin caused a substantial increase in the concentration of
mature SREBP-1 at 2 and 6 h of treatment, there was no effect

Fig. 2. Time course of the effects of T3 and insulin on levels of precursor SREBP-1 protein, mature SREBP-1 protein, and SREBP-1 mRNA
in CEH. Hepatocytes were isolated and incubated in serum-free Waymouth’s medium containing corticosterone and 25 mM glucose. At 18 h
of incubation, the medium was changed to one of the same composition. T3, insulin, or T3 plus insulin was added at this time. After 2, 6,
and 24 h of hormone treatment, cellular extracts or total RNA were prepared as described under Experimental Procedures. A: The abundance of precursor SREBP-1 in membrane fractions and mature SREBP-1 in nuclear extracts was measured by Western analyses. These data
are from a representative experiment. B: The abundance of SREBP-1 mRNA and 18S rRNA was measured using an RNase protection assay.
These data are from a representative experiment. C: Signals for precursor SREBP-1 protein and mature SREBP-1 protein from Western analyses and SREBP-1 mRNA from RNase protection analyses were quantitated. Levels of precursor SREBP-1 protein, mature SREBP-1 protein,
and SREBP-1 mRNA in hepatocytes treated with no additional hormones for 2 h were set at 1. Values are the means SEM of four experiments.
a: Mean is significantly (P 0.05) different from that of cells incubated with no additional hormones for 2 h. b: Mean is significantly (P
0.05) different from that of cells incubated with no additional hormones for 6 h. c: Mean is significantly (P 0.05) different from that of
cells incubated with no additional hormones for 24 h.

of this hormone on the concentration of SREBP-1 precursor
protein and SREBP-1 mRNA at these time points. This finding suggests that most if not all of the increase in mature
SREBP-1 concentration caused by 2 and 6 h of insulin treatment is mediated by changes in the processing of precursor
SREBP-1 to mature SREBP-1 or turnover of mature SREBP-1.
Incubating CEH with insulin for 24 h resulted in a small increase (1.7-fold) in SREBP-1 mRNA abundance. This effect
may account for the slightly greater increase in mature
SREBP-1 levels at 24 h of insulin treatment relative to 2 and
6 h of insulin treatment. The time course of the effects of T3
plus insulin on the abundance of mature SREBP-1 protein,
precursor SREBP-1 protein, and SREBP-1 mRNA was similar
to that of insulin alone except that the magnitude of the effect of T3 plus insulin on mature SREBP-1 levels at 24 h of
treatment was greater than that of insulin alone at 24 h of
treatment. The latter observation is consistent with the proposal that T3 increases the abundance of mature SREBP-1 via
a mechanism that is distinct from that mediating the increase
of mature SREBP-1 levels by insulin.
The ACC SRE-1 and T3RE constitute a response unit
that mediates the inhibitory effects of cAMP and
medium-chain fatty acids on ACC transcription
Treatment of CEH with cAMP or medium-chain fatty acids inhibits the activation of ACC transcription caused by
T3 and insulin (24–26). Previous work demonstrating that
SREBP-1 interacts with TR to augment T3-induced ACC

transcription (10) plus results of the present study demonstrating that T3 and insulin increases the concentration of
mature SREBP-1 (Figs. 1, 2) have led us to hypothesize
that SREBP-1 plays a role in mediating the inhibition of
ACC transcription by cAMP and medium-chain fatty acids.
To investigate this possibility, transient transfection experiments were performed to identify the cis-acting sequences
that conferred the inhibitory effects of cAMP and hexanoate on ACC transcription in the presence of T3 and
insulin. In our initial experiments, CEHs were transfected
with a series of constructs containing 5-deletions of ACC
promoter 2 linked to the CAT gene. In CEH transfected
with a construct containing 4,900 bp of 5-flanking DNA
(p[ACC4900/274]CAT), cAMP and hexanoate decreased promoter activity by 72% and 51%, respectively
(Fig. 3). Deletion of ACC sequences to 2,054, 854,
391, and 212, 136, and 108 bp had no effect on
cAMP and hexanoate responsiveness. Deletion of sequences containing one of the half-sites of the ACC
T3RE (108 to 94 bp) abolished the hexanoate-mediated
inhibition of ACC transcription and diminished cAMPmediated inhibition of ACC transcription by 32%. This
deletion also decreased T3-induced ACC promoter activity by 95%. Further deletion of ACC sequences to 5-end
points of 84, 59, and 41 bp had no effect on residual
cAMP responsiveness. These data suggest that the ACC
T3RE between 101 and 86 bp is required for optimal
suppression of ACC transcription by cAMP and hex-

Zhang, Yin, and Hillgartner Regulation of acetyl-CoA carboxylase by SREBP-1

361

Fig. 3. Effects of deletions of the 5-flanking region of ACC promoter 2 on transcriptional activity in the
absence and presence of cAMP or hexanoate. CEHs were transiently transfected with p[ACC4900/274]
chloramphenicol acetyltransferase (CAT) or equimolar amounts of other plasmids as described under Experimental Procedures. After transfection, cells were treated with T3 and insulin in the absence or presence
of dibutyryl cAMP or hexanoate for 48 h. Cells were then harvested, extracts prepared, and CAT assays performed. Left: The constructs used in these experiments. The number at the left of each construct is the 5end of ACC DNA in nucleotides relative to the transcription initiation site of promoter 2. The 3-end of
each construct was 274 bp. The location of the T3 response element (T3RE) (101 to 86 bp) and SRE-1
(80 to 71 bp) is indicated by the vertical lines. Right: CAT activity of cells transfected with p[ACC212/
274]CAT and treated with T3 and insulin was set at 100, and the other activities were adjusted proportionately. The effect of cAMP is the CAT activity of cells treated with T3, insulin, and cAMP expressed as a percentage of that in cells treated with T3 and insulin. The effect of hexanoate was calculated in a similar manner. The effects of cAMP and hexanoate were calculated for individual experiments and then averaged. The
results are the means SEM of six experiments. Significant differences between means within a column (P
0.05) are as follows: a versus p[ACC108/274]CAT.

anoate. In addition, ACC sequences downstream of 41
bp are also involved in conferring cAMP regulation on
ACC transcription.
To further analyze the role of the ACC T3RE in mediating the actions of cAMP and hexanoate on ACC transcription, CEHs were transfected with constructs containing fragments of the ACC gene linked to the minimal
promoter of the herpes simplex virus thymidine kinase
(TK) gene. The TK promoter alone was unresponsive to
cAMP and hexanoate (Fig. 4). When a DNA fragment
containing the ACC T3RE (108 to82 bp) was linked
to TKCAT, cAMP had no effect on promoter activity and
hexanoate caused a small decrease (20%) in promoter activity. These results suggest that sequences in addition to
the ACC T3RE are required for optimal inhibition of
transcription by cAMP and hexanoate. When a DNA fragment containing both the ACC T3RE and SRE-1 (108
to 66 bp) was linked to TKCAT, cAMP and hexanoate inhibited transcription by 52% and 60%, respectively. The
increase in cAMP and hexanoate responsiveness caused
by the inclusion of the ACC SRE-1 was not due to
changes in the spacing between the T3RE and the TK promoter, because the effects of cAMP and hexanoate on a
construct containing a mutation of the ACC SRE-1 (SRE-1
mut) in the context of p[ACC108/66]TKCAT were
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similar to those observed for p[ACC108/82]TKCAT.
In CEH transfected with a construct containing the SRE-1
alone (84 to 66 bp) linked to TKCAT, cAMP and hexanoate had no effect on promoter activity. Thus, the
ACC SRE-1 requires the presence of the ACC T3RE in
order to confer regulation of transcription by cAMP and
hexanoate. Collectively, the data in Figs. 3 and 4 suggest
that the ACC SRE-1 and T3RE constitute a response unit
that mediates the inhibitory effects of cAMP and hexanoate on gene transcription.
We next investigated the effects of the ACC SRE-1 on
the regulation of ACC promoter 2 by cAMP and hexanoate. Mutation of the ACC SRE-1 (79 to 72 bp) in
the context of the ACC promoter region extending from
108 to 274 bp decreased cAMP and hexanoate responsiveness by 43% and 61%, respectively (Fig. 5). A similar
result was obtained when the ACC SRE-1 was mutated in
the context of the ACC promoter region extending from
108 to 31. Thus, the presence of the ACC SRE-1 augments the inhibitory actions of cAMP and hexanoate on
ACC transcription. The observation that mutation of the
ACC SRE-1 does not completely inhibit cAMP responsiveness of ACC promoter 2 supports the 5-deletion data
(Fig. 3), suggesting the presence of an additional cAMP
response element(s) located downstream of 41 bp. The

3 boundary of this cAMP response element is probably
located upstream of 31 bp, because the activity of
p[ACC108/31]CAT containing the SRE-1 mutation is regulated by cAMP.
Effects of cAMP and hexanoate on the binding of nuclear
proteins to the ACC T3RE and SRE-1
On the basis of the observation that the ACC T3RE is
required for optimal inhibition of ACC transcription by
cAMP and hexanoate (Figs. 3 and 4), we have hypothesized that the effects of cAMP and hexanoate on ACC
transcription are mediated by alterations in the binding of
nuclear proteins to the ACC T3RE. Such changes in protein binding to the ACC T3RE would decrease the activity of the ACC T3RE per se and/or inhibit the ability of
the ACC T3RE to interact with the ACC SRE-1. To investigate this possibility, gel mobility shift analyses were
conducted using nuclear extracts from CEH incubated
with or without cAMP or hexanoate. We previously reported that a probe containing the ACC T3RE (108 to
82 bp) bound to four complexes designated 1 to 4 in
the order of increasing mobility (5). Complexes 1, 2, and
3 contained LXR·RXR heterodimers, whereas complex 4
contained TR·RXR heterodimers. T3 treatment for 24 h
caused a marked increase in the binding of complex 3
and complex 4 and a decrease in the binding of complex
1 and complex 2. On the basis of these data, we have proposed that T3-induced ACC transcription is mediated by
the binding of protein complexes containing TR·RXR
(complex 4) and LXR·RXR (complex 3). In Fig. 6 of the
present report, we show that addition of cAMP or hexanoate at the beginning or during the last 2 h of a 24 h incubation with T3 and insulin has no effect on the binding
of complexes 1–4. These results suggest that the inhibitory effects of cAMP and hexanoate on ACC transcription are not mediated by alterations in protein binding to
the ACC T3RE.
Data in Figs. 4 and 5 indicate that cAMP and hexanoate
suppress the ability of the ACC SRE-1 to activate ACC
transcription in the presence of T3 and insulin. cAMP and
hexanoate may decrease the activity of the ACC SRE-1 by
suppressing the induction of mature SREBP-1 levels
caused by T3 and insulin. To investigate this possibility,
Western analyses were conducted using nuclear extracts
from CEH incubated in the absence or presence of cAMP
or hexanoate. Treatment of CEH with cAMP or hexanoate
during the last 2 h of a 24 h incubation with T3 and insulin decreased the concentration of mature SREBP-1 (Fig.
7A, D). The extent of reduction in mature SREBP-1 concentration caused by cAMP and hexanoate was 71% and
52%, respectively. Similar results were obtained when
cAMP and hexanoate were added at the beginning of a 24 h
incubation with T3 and insulin. Further evidence that
cAMP and hexanoate decreased the concentration of mature SREBP-1 was obtained from gel mobility shift experiments using the ACC SRE-1 as a probe. In CEH incubated in the presence of T3 and insulin, addition of cAMP
or hexanoate decreased the binding activity of complex a
(Fig. 7B). These data suggest that cAMP and hexanoate

Fig. 4. The ACC T3RE and SRE-1 confer cAMP and hexanoate
responsiveness on a heterologous promoter. A: Sequence of the
chicken ACC gene between 108 and 66 bp. The hexameric
half-sites comprising the T3RE are indicated by arrows. The SRE-1
is boxed. The sequence of a block mutation of the SRE-1 (SRE-1
mut) is shown underneath the SRE-1. B: Fragments of the ACC
gene containing the T3RE and/or SRE-1 were linked to the minimal thymidine kinase (TK) promoter in TKCAT. CEHs were transiently transfected with these constructs and treated with T3 and insulin in the absence or presence of dibutyryl cAMP or hexanoate as
described in the legend to Fig. 3 and under Experimental Procedures. Left: Constructs used in these experiments. Numbers indicate the 5 and 3 boundaries of ACC DNA relative to the transcription initiation site of promoter 2. Right: CAT activity in CEH
transfected with p[ACC108/82]TKCAT and treated with T3
and insulin was set at 100, and the other activities were adjusted
proportionately. The effects of cAMP and hexanoate on promoter
activity were calculated as described in the legend to Fig. 3. The results are the means SEM of six experiments. Significant differences between means within a column (P 0.05) are as follows:
a versus any other construct.

inhibit ACC SRE-1 activity by decreasing the concentration of mature SREBP-1.
To investigate the mechanism for the reduction in mature SREBP-1 levels caused by cAMP and hexanoate, the
abundance of precursor SREBP-1 protein and SREBP-1
mRNA was measured in CEH incubated in the absence or
presence of cAMP or hexanoate. Addition of cAMP or
hexanoate during the last 2 h of a 24 h incubation with T3
and insulin had no effect on the concentration of precursor SREBP-1, whereas addition of cAMP or hexanoate at
the beginning of a 24 h incubation with T3 and insulin increased the concentration of precursor SREBP-1 by 1.5- to
1.7-fold (Fig. 7A, D). Thus, the decrease in the concentration of mature SREBP-1 caused by cAMP and hexanoate is
not associated with a reduction in the concentration of
precursor SREBP-1, suggesting that a posttranslational
process is involved in mediating the effects of cAMP and
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hexanoate on mature SREBP-1 levels in CEH. We next investigated whether cAMP and hexanoate modulated the
abundance of SREBP-1 mRNA. Addition of cAMP between 1 and 24 h or between 22 and 24 h of a 24 h incubation with T3 and insulin had no effect on SREBP-1 mRNA
abundance (Fig. 7C, D). In contrast, addition of hexanoate during the last 2 h of a 24 h incubation with T3
and insulin decreased SREBP-1 mRNA abundance by
51%. Similar results were obtained when hexanoate was
added at the beginning of a 24 h incubation with T3 and
insulin. These data suggest that hexanoate also regulates
the concentration of mature SREBP-1 at a pretranslational step.

DISCUSSION
Previous work from our laboratory has shown that
SREBP-1 interacts with TR on the ACC gene to enhance
T3-induced ACC transcription (10). In the present study,
we have identified a new interaction between the SREBP-1
and TR signaling pathways. T3 stimulates an increase in
the concentration of the mature, active form of SREBP-1
in CEH. These data are the first to show that T3 modulates the activity of an accessory transcription factor that
controls TR activity.
An interesting feature of the regulation of the ACC
gene in CEH is that maximal activation of transcription by
T3 requires a relatively long time ( 24 h), with most of
the increase in transcription occurring between 5 h and
24 h of hormone treatment (24). Results of previous studies analyzing the binding of nuclear proteins to the ACC
T3RE have suggested that the increase in transcription between 5 and 24 h of T3 treatment is mediated by a decrease in the binding of protein complexes containing
LXR·RXR (complexes 1 and 2) and an increase in the

binding of protein complexes containing TR·RXR (complex 4) and LXR·RXR (complex 3) (5). Results of time
course analyses in the present study suggest that alterations in SREBP-1 binding to the ACC SRE-1 also play a
role in mediating the increase in ACC transcription
caused by T3. Addition of T3 increases the concentration
of mature SREBP-1 between 5 and 24 h of hormone treatment (Fig. 2). The stimulatory effects of T3 on transcription of fatty acid synthase (6), ATP-citrate lyase (38),
stearoyl-CoA desaturase (39), and spot 14 (40) may also
be mediated, at least in part, by the increase in mature
SREBP-1 abundance caused by T3, because these genes
contain functional SREs (11, 12, 18, 41, 42).
Previous studies have shown that the ability of T3 to activate ACC transcription in CEH is enhanced by the presence of insulin in the culture medium (24). Data from the
present study indicate that insulin increases the concentration of mature SREBP-1 in CEH and that this effect is
additive with that of T3 (Figs. 1, 2). This observation provides support for a role of SREBP-1 in mediating the effects of insulin on T3-induced ACC transcription. Other
mechanisms may be involved in mediating the actions of
insulin on ACC transcription, because most of the increase in mature SREBP-1 levels caused by insulin is observed within the first 2 h of insulin treatment (Fig. 2),
whereas most of the increase in ACC transcription caused
by T3 is observed between 5 and 24 h of T3 treatment (24).
In contrast to the chicken, two isoforms of SREBP-1,
designated as SREBP-1a and SREBP-1c, are expressed in
mammals (29). These different SREBP-1 isoforms vary in
structure at their N-termini and are derived from different
promoters on the SREBP-1 gene. SREBP-1c is the predominant isoform of SREBP-1 expressed in liver; its activity is
subject to nutritional and hormonal regulation (15, 43,
44). In rat hepatocyte cultures, insulin increases the concentration of mature SREBP-1c (13–15). Thus, insulin has

Fig. 5. The ACC SRE-1 is required for optimal regulation of ACC promoter 2 activity by cAMP and hexanoate. p[ACC108/
274]CAT, p[ACC108/31]CAT, and constructs containing block mutations of the SRE-1 (SRE-1 mut) in the context of p[ACC108/
274]CAT or p[ACC108/31]CAT were transiently transfected into CEH as described under Experimental Procedures. After transfection, cells were treated with T3 and insulin in the absence or presence of dibutyryl cAMP or hexanoate as described in the legend to Fig. 3
and under Experimental Procedures. Left: The constructs used in these experiments. Numbers indicate the 5 and 3 boundaries of ACC
DNA in nucleotides relative to the transcription initiation site of promoter 2. Right: CAT activity of cells transfected with p[ACC108/
274]CAT and treated with T3 and insulin was set at 100, and the other activities were adjusted proportionately. The effects of cAMP and
hexanoate were calculated as described in the legend to Fig. 3. The results are the means SEM of five experiments. Significant differences
between means within a column (P 0.05) are as follows: a versus p[ACC108/274]CAT; b versus p[ACC108/31]CAT.
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Fig. 6. Effect of cAMP and hexanoate on the binding of hepatic
nuclear proteins to the ACC T3RE. Eighteen hours after being
placed in culture, CEHs were incubated in Waymouth’s medium
containing corticosterone, insulin, and 25 mM glucose with or without
T3, T3 plus dibutyryl cAMP, or T3 plus hexanoate for the indicated
times. Cells were harvested and nuclear extracts were prepared as
described in Experimental Procedures. Nuclear extracts were subjected to gel mobility shift analyses using an oligonucleotide probe
containing the ACC T3RE (108 to 82 bp). Specific proteinDNA complexes are indicated by arrows. Previous studies have
shown that complexes 1, 2, and 3 contain liver X receptor
(LXR)·retinoid X receptor (RXR) heterodimers, whereas complex
4 contains nuclear T3 receptor (TR)·RXR heterodimers (5). These
data are representative of five experiments employing independent
preparations of nuclear extract.

similar effects on the concentration of mature SREBP-1c
in rat hepatocytes and the concentration of mature
SREBP-1 in CEH. Further analyses have shown that insulin-induced increase in mature SREBP-1c abundance in
rat hepatocytes is mediated primarily by changes in
SREBP-1c mRNA abundance (13–15). These findings contrast with those of the present study, suggesting that posttranslational processes play a prominent role in mediating
the effects of insulin on mature SREBP-1 levels in CEH.
The reason for the differences between avians and mammals in the diversity of SREBP-1 isoforms and the mechanism mediating the effects of insulin on mature SREBP-1
levels is not clear. They may reflect subtle class-dependent
differences in the role of SREBP-1 in the control of lipogenesis and/or other metabolic processes in liver.
In addition to participating in the activation of ACC transcription by T3 and insulin, SREBP-1 plays a role in mediating
the inhibition of ACC transcription caused by cAMP. Results
from transfection, DNA binding, and Western analyses indicate that cAMP inhibits ACC transcription in part by repressing the ability of T3 and insulin to increase mature SREBP-1
levels (Figs. 3–5, 7). This effect, in turn, disrupts the positive
interaction between SREBP-1 and T3-bound TR on the

ACC gene. cAMP causes a rapid decrease ( 2 h) in mature
SREBP-1 concentration that precedes or parallels the reduction in ACC transcription caused by cAMP (24). To our
knowledge, these observations are the first to establish a role
for SREBP-1 in mediating the inhibitory effects of cAMP on lipogenic gene transcription.
cAMP inhibits the transcription of other lipogenic
genes, such as glucokinase, l-pyruvate kinase, fatty acid
synthase, malic enzyme, glycerol-3-phosphate acyltransferase, and spot 14 (1). For some of these genes, the
mechanism by which cAMP inhibits transcription has
been analyzed. For example, in rat hepatoma cells, the inhibitory actions of cAMP on fatty acid synthase transcription are mediated by an inverted CCAAT box in the proximal promoter region of the fatty acid synthase gene (45).
This element constitutively binds the transcription factor,
nuclear factor-Y (46). How cAMP modulates nuclear factor-Y activity is presently not known. In CEH, inhibition of
malic enzyme transcription by cAMP is mediated by at
least four cis-acting elements in the malic enzyme 5-flanking
DNA (47). One of these elements binds c-Fos and activating transcription factor-2 in CEH incubated in the presence of cAMP. The mechanism by which c-Fos/activating
transcription factor-2 inhibits malic enzyme transcription
is presently not known. In rat hepatocytes, inhibition of
l-pyruvate kinase transcription by cAMP is mediated by
two contiguous cis-acting elements referred to as L3 and
L4 (48). These elements also mediate the stimulatory
effect of glucose on l-pyruvate kinase transcription. L3
binds the hepatocyte nuclear factor-4 (HNF-4) and L4
binds ChREBP (2, 49). Both HNF-4 and ChREBP activate
l-pyruvate kinase transcription. Recent work has shown
that protein kinase A phosphorylates ChREBP at Ser196
and Thr666, causing a block in the transport of ChREBP
from the cytoplasm to the nucleus and a decrease in the
binding of ChREBP to the L4 element (2). Protein kinase
A also phosphorylates HNF-4, causing a decrease in the
binding of HNF-4 to the L3 element (49). Thus, cAMP inhibits l-pyruvate kinase transcription by repressing the
stimulatory effects of HNF-4 and ChREBP on transcription. These findings, in combination with those of the
present study, indicate that a wide variety of mechanisms
are involved in mediating the inhibitory actions of cAMP
on lipogenic gene transcription.
Results of the present study indicate that SREBP-1 also
plays a role in mediating the inhibitory effects of hexanoate on ACC transcription. As observed with cAMP,
hexanoate rapidly decreases ( 2 h) the concentration of
mature SREBP-1 in CEH incubated in the presence of T3
and insulin (Fig. 7). Results from Western and Northern
analyses suggest that the reduction in mature SREBP-1 levels caused by hexanoate is mediated by both pretranslational and posttranslational processes. In contrast, the inhibitory effect of cAMP on mature SREBP-1 levels appears
to be mediated solely by a posttranslational mechanism.
These observations suggest that hexanoate and cAMP act
through common as well as separate signaling pathways to
suppress mature SREBP-1 levels in CEH.
Recently, Kawaguchi et al. (16) have shown that acetate,
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Fig. 7. cAMP and hexanoate suppress the stimulatory effects of T3 and insulin on the concentration of mature SREBP-1 in CEH. Eighteen
hours after being placed in culture, CEHs were incubated in Waymouth’s medium containing corticosterone, insulin, 25 mM glucose, and
T3 with or without dibutyryl cAMP or hexanoate for the indicated times. Cell extracts or total RNA were prepared as described in Experimental Procedures. A: The abundance of precursor SREBP-1 in membrane fractions and mature SREBP-1 in nuclear extracts was measured
by Western analyses. These data are from a representative experiment. B: Gel mobility shift assays were per formed using nuclear extracts
from hepatocytes and an oligonucleotide probe containing the ACC SRE-1 (84 to 66 bp). Positions of specific protein-DNA complexes
(arrows) and nonspecific complexes (asterisk) are indicated. C: The abundance of SREBP-1 mRNA and 18S rRNA was measured using an
RNase protection assay. These data are from a representative experiment. D: Signals for precursor SREBP-1 protein and mature SREBP-1
protein from Western analyses and SREBP-1 mRNA from RNase protection analyses were quantitated. Levels of precursor SREBP-1 protein,
mature SREBP-1 protein, and SREBP-1 mRNA in hepatocytes treated with T3 and insulin without cAMP and hexanoate were set at 1. Values
are the means SEM of four experiments. a: mean is significantly (P 0.05) different from that of cells treated with T3 and insulin without
cAMP and hexanoate.

octanoate, and palmitate inhibit l-pyruvate kinase transcription in rat hepatocytes by abolishing the binding of
ChREBP to the L4 element. This effect is mediated by an
increase in the phosphorylation of ChREBP at Ser568 by
AMP-activated protein kinase. Recent work by Zhou et al.
(50) suggests that AMP-activated protein kinase also controls SREBP-1 activity. Treatment of rat hepatocytes with
agents that stimulate AMP-activated protein kinase activity
(5-amino-imidazole carboxamide riboside and the antidiabetic drug, metformin) results in a reduction SREBP-1
protein levels and SREBP-1 mRNA abundance. These
agents also inhibit expression of ACC and fatty acid synthase in rat hepatocytes (50, 51). We postulate that hexanoate decreases mature SREBP-1 levels in CEH by stimulating the activity of AMP-activated protein kinase.
Alterations in AMP-activated protein kinase activity may
directly or indirectly regulate the activity of factors that
control the abundance of SREBP-1 mRNA and/or the
processing of precursor SREBP-1 to mature SREBP-1. Experiments are underway to explore this hypothesis.
In addition to hexanoate and octanoate, long-chain
polyunsaturated fatty acids (PUFAs) inhibit lipogenic
gene transcription in hepatocytes incubated in the presence of insulin and T3 (52). In the case of the genes for
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fatty acid synthase, stearoyl-CoA desaturase, and spot 14,
inhibition of transcription by PUFA is mediated, at least in
part, by a reduction in the concentration of mature
SREBP-1 (18, 41, 53). Further analyses have shown that
the decrease in mature SREBP-1 concentration caused by
PUFA is associated with a reduction in SREBP-1 mRNA
abundance (18, 20). The decrease in mature SREBP-1
concentration caused by hexanoate is also associated with
a reduction in SREBP-1 mRNA abundance (Fig. 7). On
the basis of these observations, we postulate that the active
metabolite(s) mediating the effect of PUFAs on SREBP-1
expression is similar to the metabolite mediating the effect of hexanoate on SREBP-1 expression. Further analysis
of the mechanisms by which medium-chain fatty acids and
PUFAs control SREBP-1 activity should aid in identifying
this metabolite.
In summary, we have shown that SREBP-1 is an accessory transcription factor that plays an active and central
role in the hormonal and nutritional regulation of ACC
transcription in hepatocytes. Through interactions with
the TR, SREBP-1 functions as an integrator of multiple
stimulatory and inhibitory signals that influence rates of
lipogenesis. We propose that, in intact animals, this regulatory system allows for the rapid and fine control of

ACC transcription in response to alterations in dietary
carbohydrate intake.
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